1262 related articles for article (PubMed ID: 29474870)
1. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
3. [The prognostic significance of pretransplantation evaluation of IPSS-R and WPSS in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation].
Lu CQ; Hou C; Wang P; Zhang LW; Fan Y; Wu DP; Xu Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):247-254. PubMed ID: 35405784
[No Abstract] [Full Text] [Related]
4. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.
Gauthier J; Damaj G; Langlois C; Robin M; Michallet M; Chevallier P; Beguin Y; N'guyen S; Bories P; Blaise D; Cornillon J; Clavert A; Mohty M; Huynh A; Thiébaut-Bertrand A; Vigouroux S; Duhamel A; Yakoub-Agha I
Transplantation; 2015 Aug; 99(8):1672-80. PubMed ID: 25769079
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.
Oran B; Kongtim P; Popat U; de Lima M; Jabbour E; Lu X; Chen J; Rondon G; Kebriaei P; Ahmed S; Andersson B; Alousi A; Ciurea S; Shpall E; Champlin RE
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1618-25. PubMed ID: 24953017
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
7. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
[TBL] [Abstract][Full Text] [Related]
8. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.
Scheid C; de Wreede L; van Biezen A; Koenecke C; Göhring G; Volin L; Maertens J; Finke J; Passweg J; Beelen D; Cornelissen JJ; Itälä-Remes M; Chevallier P; Russell N; Petersen E; Milpied N; Richard Espiga C; Peniket A; Sierra J; Mufti G; Crawley C; Veelken JH; Ljungman P; Cahn JY; Alessandrino EP; de Witte T; Robin M; Kröger N
Bone Marrow Transplant; 2017 Nov; 52(11):1519-1525. PubMed ID: 28892084
[TBL] [Abstract][Full Text] [Related]
9. Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.
Yahng SA; Jeon YW; Yoon JH; Shin SH; Lee SE; Choi YS; Kim DY; Lee JH; Cho BS; Eom KS; Lee S; Min CK; Kim HJ; Lee JW; Lee KH; Min WS; Lee JH; Kim YJ
Bone Marrow Transplant; 2017 Apr; 52(4):522-531. PubMed ID: 27892952
[TBL] [Abstract][Full Text] [Related]
10. [Impact of induced therapy before allogeneic hematopoietic stem-cell transplantation for higher-risk myelodysplastic syndrome: experience of single centre].
Zhou JY; He GS; Wu DP; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu ZZ; Ma X; Miao M; Xue SL; Wang Y
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3185-8. PubMed ID: 24405537
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
12. [The clinical analysis of allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-identical siblings in 95 patients with myelodysplastic syndrome].
Zhao T; Huang X; Liu D; Wang J; Zhang X; Wang Y; Han W; Chen H; Chen Y; Wang F; Liu K; Xu L
Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):89-93. PubMed ID: 24767157
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.
Potter VT; Iacobelli S; van Biezen A; Maertens J; Bourhis JH; Passweg JR; Yakhoub-Agha I; Tabrizi R; Bay JO; Chevallier P; Chalandon Y; Huynh A; Cahn JY; Ljungman P; Craddock C; Lenhoff S; Russell NH; Fegueux N; Socié G; Bruno B; Meijer E; Mufti GJ; de Witte T; Robin M; Kröger N
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1615-1620. PubMed ID: 27264633
[TBL] [Abstract][Full Text] [Related]
14. Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies.
Guièze R; Damaj G; Pereira B; Robin M; Chevallier P; Michallet M; Vigouroux S; Beguin Y; Blaise D; El Cheikh J; Roos-Weil D; Thiebaut A; Rohrlich PS; Huynh A; Cornillon J; Contentin N; Suarez F; Lioure B; Mohty M; Maillard N; Clement L; François S; Guillerm G; Yakoub-Agha I
Biol Blood Marrow Transplant; 2016 Feb; 22(2):240-247. PubMed ID: 26256942
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.
Della Porta MG; Alessandrino EP; Bacigalupo A; van Lint MT; Malcovati L; Pascutto C; Falda M; Bernardi M; Onida F; Guidi S; Iori AP; Cerretti R; Marenco P; Pioltelli P; Angelucci E; Oneto R; Ripamonti F; Bernasconi P; Bosi A; Cazzola M; Rambaldi A;
Blood; 2014 Apr; 123(15):2333-42. PubMed ID: 24558201
[TBL] [Abstract][Full Text] [Related]
17. [Outcomes of 138 myelodysplastic syndrome patients with HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation].
Wang QQ; Liu ZX; Zhao XL; Zhang GX; Yao JF; Zheng XH; Zhang LN; Shen YY; Zhao XL; He Y; Huang Y; Zhang RL; Wei JL; Ma QL; Pang AM; Yang DL; Zhai WH; Jiang EL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):132-137. PubMed ID: 32135630
[No Abstract] [Full Text] [Related]
18. Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome.
Oshikawa G; Yoshioka K; Takahashi Y; Shingai N; Ikegawa S; Kobayashil T; Doki N; Kakihana K; Ohashi K; Sakamaki H
Pathol Oncol Res; 2015 Sep; 21(4):1037-43. PubMed ID: 25837848
[TBL] [Abstract][Full Text] [Related]
19. Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.
Gerds AT; Woo Ahn K; Hu ZH; Abdel-Azim H; Akpek G; Aljurf M; Ballen KK; Beitinjaneh A; Bacher U; Cahn JY; Chhabra S; Cutler C; Daly A; DeFilipp Z; Gale RP; Gergis U; Grunwald MR; Hale GA; Hamilton BK; Jagasia M; Kamble RT; Kindwall-Keller T; Nishihori T; Olsson RF; Ramanathan M; Saad AA; Solh M; Ustun C; Valcárcel D; Warlick E; Wirk BM; Kalaycio M; Alyea E; Popat U; Sobecks R; Saber W
Biol Blood Marrow Transplant; 2017 Jun; 23(6):971-979. PubMed ID: 28288952
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
